PAPER Snape M, Lee HG, Casadesus G, Smith MA
SEARCH RESULTS
329930 RESULTS
PAPER Fuller S, Münch G, Steele M
Activated astrocytes: a therapeutic target in Alzheimer's disease?
Expert Rev Neurother. 2009 Nov;9(11):1585-94. PubMed: 19903019PAPER Lee HP, Casadesus G, Zhu X, Lee HG, Perry G, Smith MA, Gustaw-Rothenberg K, Lerner A
All-trans retinoic acid as a novel therapeutic strategy for Alzheimer's disease.
Expert Rev Neurother. 2009 Nov;9(11):1615-21. PubMed: 19903021PAPER Rezai-Zadeh K, Gate D, Szekely CA, Town T
Can peripheral leukocytes be used as Alzheimer's disease biomarkers?
Expert Rev Neurother. 2009 Nov;9(11):1623-33. PubMed: 19903022PAPER Origlia N, Arancio O, Domenici L, Yan SS
MAPK, beta-amyloid and synaptic dysfunction: the role of RAGE.
Expert Rev Neurother. 2009 Nov;9(11):1635-45. PubMed: 19903023PAPER Hanger DP, Seereeram A, Noble W
Mediators of tau phosphorylation in the pathogenesis of Alzheimer's disease.
Expert Rev Neurother. 2009 Nov;9(11):1647-66. PubMed: 19903024PAPER Tsuno N, Homma A
What is the association between depression and Alzheimer's disease?
Expert Rev Neurother. 2009 Nov;9(11):1667-76. PubMed: 19903025PAPER Stranahan AM, Zhou Y, Martin B, Maudsley S
Pharmacomimetics of exercise: novel approaches for hippocampally-targeted neuroprotective agents.
Curr Med Chem. 2009;16(35):4668-78. PubMed: 19903142PAPER Supnet C, Noonan C, Richard K, Bradley J, Mayne M
Up-regulation of the type 3 ryanodine receptor is neuroprotective in the TgCRND8 mouse model of Alzheimer's disease.
J Neurochem. 2010 Jan;112(2):356-65. PubMed: 19903243PAPER Walker AK, Farg MA, Bye CR, McLean CA, Horne MK, Atkin JD
Protein disulphide isomerase protects against protein aggregation and is S-nitrosylated in amyotrophic lateral sclerosis.
Brain. 2010 Jan;133(Pt 1):105-16. PubMed: 19903735PAPER Fraser T, Tayler H, Love S
Fatty acid composition of frontal, temporal and parietal neocortex in the normal human brain and in Alzheimer's disease.
Neurochem Res. 2010 Mar;35(3):503-13. PubMed: 19904605PAPER Rabinowitz YG, Hartlaub MG, Saenz EC, Thompson LW, Gallagher-Thompson D
Is religious coping associated with cumulative health risk? An examination of religious coping styles and health behavior patterns in Alzheimer's dementia caregivers.
J Relig Health. 2010 Dec;49(4):498-512. PubMed: 19904608PAPER Garai K, Mustafi SM, Baban B, Frieden C
Structural differences between apolipoprotein E3 and E4 as measured by (19)F NMR.
Protein Sci. 2010 Jan;19(1):66-74. PubMed: 19904741PAPER Ramakers IH, Visser PJ, Aalten P, Kester A, Jolles J, Verhey FR
Affective symptoms as predictors of Alzheimer's disease in subjects with mild cognitive impairment: a 10-year follow-up study.
Psychol Med. 2010 Jul;40(7):1193-201. PubMed: 19903364Frederic Calon on Medical Foods—Fallback Option for Elusive AD Drug Status?
COMMENT I think it would have been a major advantage to get Ketasyn/AC1202 FDA-approved as a drug. Ketasyn/AC1202 could have then been used by health professionals and prescribed to the right persons. There is a strong rationale in using medium chain triglyceride
Current Filters
No filters selected